Federal contract award
HHSO10033002T
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | HHSO100201500008I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $4.2M |
| Current contract value | $4.2M |
| Potential contract value / ceiling | $6.8M |
| Start date | Sep 20, 2017 |
| Current end date | Jul 31, 2022 |
| Potential end date | Jul 31, 2022 |
| Latest award activity | Apr 25, 2022 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 25, 2022 | P00007 | $0 | EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Nov 3, 2021 | P00006 | $0 | EO14042 - EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Sep 8, 2021 | P00005 | $0 | EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Sep 19, 2020 | P00004 | $740.9K | EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Apr 7, 2020 | P00003 | $999.9K | EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Mar 29, 2020 | P00002 | $0 | EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Sep 19, 2019 | P00001 | $0 | ?EVALUATION OF COAGULATION PATHWAY-TARGETING DRUGS IN THE RABBIT MODEL OF ACUTE RADIATION SYNDROME (ARS) FOR POTENTIAL NEW INDICATIONS AS ARS MEDICAL COUNTERMEASURES? |
| Sep 20, 2017 | 0 | $2.5M | IGF::OT::IGF |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.